...
首页> 外文期刊>Experimental Biology and Medicine: Journal of the Society for Experimental Biology and Medicine >Examining the technical feasibility of prostate cancer molecular imaging by transrectal photoacoustic tomography with transurethral illumination
【24h】

Examining the technical feasibility of prostate cancer molecular imaging by transrectal photoacoustic tomography with transurethral illumination

机译:用经尿道照明检查久理光声断层扫描前列腺癌分子成像的技术可行性

获取原文
获取原文并翻译 | 示例

摘要

To pave the road toward clinical application of photoacoustic imaging in prostate cancer (PCa) diagnosis, we studied the technical feasibility and performance of transrectal photoacoustic (PA) imaging in mapping the indocyanine green (ICG) contrast agent, which is approved by FDA, in entire prostates by using light illumination via the urethral track. Experiments were conducted on a clinically relevant ex vivo model involving whole human prostates harvested from radical prostatectomy. The light source placed in the urethral track was an array of light emitting diodes (LEDs), illuminating the prostate with a delivered light power on the urethral wall within the safety limit. A dual-modality imaging system acquired PA and ultrasound (US) images simultaneously in the same way as in transrectal ultrasound (TRUS), with the US imaging presenting the tissue structure and PA imaging detecting the ICG solution. The imaging results demonstrated that tubes containing ICG solution at different concentrations can be detected at different positions in the prostate within a 2 cm range around from the urethral wall. Considering the sizes of regular human prostates, the proposed transurethral illumination in combination with transrectal US detection can facilitate PA molecular imaging over the entire prostate in a non-invasive manner, which makes it possible to further improve the PCa diagnosing efficiency with better molecular sensitivity and resulted better biopsy accuracy and much reduced pain for patients. Impact statement Differentiating cancerous tissues from healthy ones is critical in the diagnosis of prostate cancer (PCa). However, due to the low sensitivity of ultrasound (US) imaging to cancerous tissues, transrectal ultrasound (TRUS) guided biopsies, current standard procedure for diagnosing PCa, suffer from low core yield, leading to under-sampling and under-grading of clinically significant tumors. Via the experiment on the ex vivo human prostates, we evaluated the translational potential of photoacoustic imaging (PAI) based on a safe light emitting diodes (LED) source for detecting the molecular information in deep human prostate. We showed that transurethral light illumination in combination with transrectal US detection can facilitate PA molecular imaging over an entire human prostate in a non-invasive manner. The success of this study in the clinically relevant ex vivo human prostate model suggested a new strategy for PA and US combined imaging and detection of PCa.
机译:为了铺设走向前列腺癌(PCA)诊断的光声成像的临床应用,我们研究了通过FDA批准的吲哚菁绿(ICG)造影剂在映射近吲哚菁绿(ICG)造影剂中的技术可行性和性能通过使用尿道轨道使用光照射整个前列腺。在涉及从自由基前列腺切除术中收获的整个人前列腺的临床相关的前体内模型进行了实验。放置在尿道轨道中的光源是发光二极管(LED)的阵列,在安全极限内用尿道壁上的输送光功率照射前列腺。双模成像系统以与经委托超声(TRU)相同的方式获取PA和超声(US)图像,其中US成像呈现组织结构和PA成像检测ICG溶液。成像结果表明,在从尿道壁周围的2cm范围内的前列腺内的不同位置处检测含有不同浓度的ICG溶液的管。考虑到常规人类前列腺的尺寸,所提出的经尿道照明与脑外美国检测组合可以促进以非侵入方式在整个前列腺上的PA分子成像,这使得可以进一步提高PCA诊断效率,具有更好的分子敏感性和导致更好的活组织检查准确性和患者疼痛大大减少。将来自健康癌症的癌组织的影响声明在诊断前列腺癌(PCA)中至关重要。然而,由于超声(US)成像对癌组织的敏感性,癌症超声(TRUS)引导活组织检查,目前诊断PCA的标准程序患有低核心产量,导致临床上的缺失和低于分级肿瘤。通过在离体人道前列腺上的实验,我们评估了基于安全发光二极管(LED)源的光声成像(PAI)的平移电位,用于检测深部人前列腺的分子信息。我们表明,经尿道射光照射与脑外美国检测组合可以促进以非侵入方式在整个人类前列腺上进行PA分子成像。本研究在临床相关的前体内人道前列腺模型中的成功建议了PA和美国联合成像和PCA的综合成像和检测的新策略。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号